The Future of Immunotherapies in Advanced/Recurrent Endometrial Cancer Treatment

Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

Based on findings from the phase 3 MIRASOL trial, investigators plan to submit a supplemental biologics license application for mirvetuximab soravtansine in folate receptor α–positive platinum-resistant ovarian cancer.

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

The European Medicines Agency validates the potential indication of dostarlimab/chemotherapy in mismatch repair deficient/microsatellite instability–high endometrial cancer based on the phase 3 RUBY trial.

Patients with platinum-resistant high-grade serous carcinoma have little overall survival benefit with the addition of vistusertib to weekly paclitaxel.